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 ABSTRACT 
Objective:  The objective of this selective EBM review is to determine whether or not 
Sofosbuvir plus Ribavirin is safer and more effective than Peginterferon plus Ribavirin 
for treatment of chronic Hepatitis C Virus infection in treatment-naïve patients. 
Study Design: Systematic review of three English language primary studies, published in 
2013. 
Data Sources: Three randomized control trials, two of which are open-label, active-
controlled and one that is double-blind, placebo-controlled, comparing Sofosbuvir and 
Ribavirin versus other chronic HCV modalities found via PubMed in peer-reviewed 
journals. 
Outcomes Measured:  Safety was measured by self-reported adverse events, routine 
laboratory tests, physical exams, vital signs, and electrocardiography and graded using 
the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse 
Events.  Efficacy was determined by sustained virological response at 12 or 24 weeks 
post-treatment (SVR12 and SVR24, respectively), which is classified as a HCV RNA 
concentration below the limit of detection of 15 IU/mL or 25 IU/mL 
Results: Gane, et al5 compared the treatment effects of 400mg Sofosbuvir and Ribavirin 
(RBV) with that of Sofosbuvir plus RBV and Peginterferon (PEG) for 12 weeks in 
patients with chronic HCV.  Analysis resulted in an equal incidence of SVR24, but with 
less adverse events in the experimental group.  In Lawitz, Lalezari, et al6, patients 
received 12 weeks with either 400mg Sofosbuvir, RBV, and PEG or placebo, PEG, and 
RBV.  SVR24 was higher in the Sofosbuvir group, however more adverse events of 
fatigue were reported compared to the placebo group.  Lawitz, Mangia, et al7 examined 
the difference in treatment with 12 weeks of 400mg Sofosbuvir and RBV versus 24 
weeks of PEG and RBV.  Statistical analysis showed an equal rate of SVR12 between the 
two groups, yet treatment with Sofosbuvir was safer.  
Conclusions:  It can be deduced from these three RCTs that Sofosbuvir plus RBV is 
safer, yet, statistically, nearly equal in efficacy to treatment with PEG and RBV.  Given 
that PEG is a weekly injection with many unfavorable side effects, it would be more 
beneficial to receive treatment with Sofosbuvir and RBV for treatment of chronic HCV 
infection 
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INTRODUCTION 
 Hepatitis C Virus (HCV) is an infectious RNA virus that invades the liver and is 
transmitted primarily via exposure to infected blood, such as through intravenous drug abuse.1  
Following an acute HCV infection, approximately 85% of cases become chronic, or when the 
infection lasts greater than 3-6 months. 1, 2  This paper evaluates three randomized control trials 
(RCTs) – two of which are open-label, active-controlled and one which is double-blind, placebo-
controlled – comparing the safety and efficacy of Sofosbuvir and Ribavirin in the treatment of 
chronic HCV. 
The Center for Disease Control and Prevention (CDC) has estimated that chronic HCV 
infection affects 3.2 million people in the United States alone.2  In 2011, it was projected that the 
total healthcare cost associated with HCV infection was an average of $6.5 billion.3  Of those 
infected with HCV, 75-85% will become a chronic infection, 60-70% will develop chronic liver 
disease, 5-20% will develop cirrhosis, and 1-5% will die.2  Additionally, chronic HCV infection 
can increase one’s chance of developing hepatocellular carcinoma and, due in part to its high 
prevalence in the population, is the leading cause for liver transplantation.4 
Unfortunately, there is no vaccine available to protect against HCV, only initiation of 
preventative measures.  Once infected, a person with HCV will usually be asymptomatic unless 
severe liver disease and consequences ensue.2   Furthermore, during the acute phase, liver 
function tests may be elevated, but once the HCV becomes chronic, the levels may normalize.1, 2 
HCV infection, then, may only be exposed on routine laboratory screening.4  HCV infection is 
determined by detection of anti-HCV antibodies through enzyme immunoassay (EIA).  The 
HCV can be further quantified by its RNA concentration through polymerase chain reaction 
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(PCR).1  There are 6 major genotypes of HCV that are recognized, with genotype 1 being the 
most common.2 
The mainstay of treatment for chronic HCV infection has been a combination of 
anywhere from one to three different drugs.  The most utilized method is treatment with 
Peginterferon-alfa 2a (PEG), a weekly subcutaneous injection, for 24-48 weeks.5  Not only does 
PEG carry many side effects such as cytopenia and flu-like symptoms, but also many patients are 
reluctant, or even unable, to adhere to the once weekly injections. 5  Although PEG can be 
administered as a monotherapy, efficacy is rather low.  The nucleoside inhibitor Ribavirin is used 
as an adjunctive treatment, boosting the effectiveness of PEG and other therapies.  Even with the 
combination of ribavirin, however, the sustained virologic response (SVR) rate may be anywhere 
from 45-80%, depending upon the HCV genotype.  In the presence of liver disease or other 
comorbidities, the SVR may be even lower.1   
Newer drugs used to combat chronic HCV include the protease inhibitors Telaprevir and 
Boceprevir, both of which were approved by the FDA in 2011.  Although either of these drugs in 
combination with PEG and ribavirin increased the efficacy of treatment to a SVR rate from 66-
75% in genotype 1 patients, effective in other genotypes has not been studied.  Additionally, 
dosing schedules, drug interactions, and side effects of these drugs have limited their extensive 
use in chronic HCV treatment.6 
A nucleotide polymerase inhibitor, Sofosbuvir, is the newest drug on the market for the 
treatment of chronic HCV infection.  FDA approved in December 2013, Sofosbuvir can be given 
as a once daily oral dose and is thought to be safer and more effective and efficient than the 
current treatment modalities. 
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OBJECTIVE 
The objective of this selective EBM review is to determine whether or not Sofosbuvir 
plus Ribavirin is safer and more effective than Peginterferon plus Ribavirin for treatment of 
chronic Hepatitis C Virus in treatment-naïve patients. 
 
METHODS 
Specific criteria were utilized in the selection of studies to establish as much parallel as 
possible for proper comparison.  The populations studied included previously untreated men and 
women 18 years of age or older with chronic HCV infection.  All three interventions included 
the once-daily oral administration of Sofosbuvir 400mg and Ribavirin (RBV).  In one study, the 
intervention also included a once-weekly injection of PEG.  For the two interventions of 
Sofosbuvir plus RBV, one study compared it to treatment with the addition of PEG and the other 
study compared it to PEG plus RBV.  The third intervention, Sofosbuvir plus PEG and RBV, 
was compared to a placebo plus PEG and RBV.  The three studies included in this systematic 
review were randomized control trials (RCTs), each measuring both safety and efficacy.  Two of 
the RCTs were open-label, active-controlled and the other one was double-blind, placebo-
controlled.   
 Research was done by the author using the key words “Sofosbuvir,” “chronic HCV,” and 
“HCV treatment” via the PubMed database.  All articles were in English and published in peer-
reviewed journals in 2013.  Articles were chosen according to their relevance to the clinical 
question with outcomes that were patient oriented (POEMs) 
Inclusion criteria contained studies that were RCTs and included patients who were 18 
years and older with chronic HCV infection (Table 1).  Exclusion criteria included significant 
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comorbidities, such as Hepatitis B infection or Human Immunodeficiency Virus (HIV), and 
previous treatment for their HCV infection (Table 1). Statistics reported in the studies included 
sustained virologic response (SVR) rate, 95% confidence interval (CI), and p-values.  The author 
calculated relative risk reduction (RRR), absolute risk increase (ARI), absolute risk reduction 
(ARR), numbers needed to harm (NNH), and numbers needed to treat (NNT). 
 
 Table 1: Demographics and characteristics of included studies 
Study Type # of pts 
Age 
(yrs) Inclusion Criteria Exclusion Criteria W/D Interventions 
Gane,   
et al5 
2013 
RCT 21 18+ ≥18 y/o; Tx naïve; 
Chronic HCV 
infection (serum HCV 
RNA level, >50,000 
IU/mL) 
Cirrhosis; HepB or 
HIV infection 
0 Sofosbuvir 
400mg plus 
Ribavirin (RBV) 
VS. Sofosbuvir 
400mg plus 
RBV and 
Peginterferon 
(PEG)  
Lawitz, 
Lalezari 
et al6 
2013 
RCT 73 18-
70 
18-70 y/o; Tx naïve; 
Chronic HCV 
genotype 1 infection; 
[HCV RNA] ≥50,000 
IU/mL; Adequate 
hematologic and 
biochemical 
parameters 
Cirrhosis; HepB or 
HIV infection; 
Psychiatric illness; 
Pulmonary or cardiac 
disease; Seizure 
disorder or other 
serious comorbid 
disorders 
16 Sofosbuvir 
400mg plus 
RBV and PEG 
VS. Placebo plus 
PEG and RBV 
Lawitz, 
Mangia 
et al7 
2013 
RCT 499 18+ ≥18 y/o; Tx naïve; 
BMI of 18 kg/m;  
Chronic genotype 2 or 
3 HCV infection with 
serum HCV RNA 
≥10,000 IU/mL; 
Subjects or their 
partner(s) must be of 
non-childbearing 
potential or use 
effective 
contraception until 6 
months after the last 
dose of study 
medication 
HepB or HIV 
infection; liver, 
pulmonary, or cardiac 
disease; psychiatric 
illness, immunologic 
disorder; 
hemoglobinopathy; 
seizure disorder or 
anticonvulsant use, 
poorly controlled 
diabetes; cancer; 
acute pancreatitis; 
abnormal 
hematologic & 
biochemical 
parameters 
36 Sofosbuvir 
400mg plus 
RBV VS.  
PEG plus RBV 
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OUTCOMES MEASURED 
In each of the three RCTs, safety was measured by self-reported adverse events, such as 
fatigue and headache, and graded using the Division of AIDS Table for Grading the Severity of 
Adult and Pediatric Adverse Events.  All three studies determined efficacy by the sustained 
virological response at 12 and 24 weeks post-treatment (SVR12 and SVR24, respectively), 
which is classified by a HCV RNA concentration below the limit of detection of 15 IU/mL or 25 
IU/mL, depending upon the lab used.  For each trial, HCV RNA was quantified using the 
COBAS AmpliPrep/COBAS TaqMan HCV Test.  It has been shown that SVR12 and SVR24 are 
highly correlated with virus eradication signifying no further need for treatment.  Furthermore, 
these endpoints greatly reduce HCV complications, including mortality, as well as decrease the 
chance of a relapse.8 
 
RESULTS  
 This systematic review assesses three RCTs for the efficacy and tolerability of Sofosbuvir 
plus Ribavirin (RBV) compared to other modalities involving Peginterferon (PEG) for treatment 
of chronic HCV infection.  Each of the trials contained comparable study designs with 
dichotomous data, which was used in intention-to-treat analysis.  Additionally, all analysis was 
performed with a 95% confidence interval (95% CI).   
In the first study, Gane et al5 enrolled 21 patients with chronic HCV genotypes 2 and 3 
into an open-label, active-controlled RCT.  All 21 patients received 12 weeks of 400mg 
Sofosbuvir plus RBV.  11 of the 21 patients were randomized to the control group, which 
received 12 weeks of concurrent PEG treatment.  Enrollees were followed for 24 weeks post-
treatment.  Every patient completed the trial and acquired sustained virological response (SVR) 
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at 24 weeks post-treatment.  With a 95% CI (69 to 100), statistical analysis of the experimental 
group (experimental event rate, or EER) in comparison with the control group (control event 
rate, or CER) revealed a relative benefit increase (RBI), an absolute benefit increase (ABI), and a 
numbers needed to treat (NNT) of 0 (Table 2). 
Gane et al5 also addressed the safety of treatment with Sofosbuvir and Ribavirin.  The 
most common self-reported adverse events during the trial were headache, fatigue, insomnia, 
nausea, rash, and anemia.  In regards to fatigue, 45% of patients in the control group (CER) 
reported the symptom as opposed to 10% in the experimental group (EER).  This resulted in a 
calculated relative risk reduction (RRR) of -77.8%, an absolute risk reduction (ARR) of -35%, 
and a number needed to harm (NNH) of -2 (Table 3).  This negative NNH means that for every 2 
patients treated, one fewer will experience the adverse event of fatigue in the experimental group 
compared to the control group. 
In Lawitz, Lalezari and colleagues6, a double-blind, placebo-controlled RCT, 48 patients 
with HCV genotype 1 were assigned to the experimental group to receive treatment for 12 weeks 
with 400mg Sofosbuvir, RBV, and PEG.  26 patients, placed in the control group, were allotted 
to receive placebo, PEG, and RBV for 12 weeks.  Of the 47 people who began treatment in the 
experimental group and 26 who started in the control group, 42 and 14 people completed the 
study, respectively.  However, intention-to-treat analysis included everyone who began 
treatment. 
In the Sofosbuvir group, 89% of patients acquired sustained virological response (SVR) 
at 24 weeks post-treatment (EER) as opposed to 58% of patients in the placebo group (CER).  As 
shown in Table 2, statistical analysis with a 95% CI (11 to 49) exposed a RBI of 58%, an ABI of 
14%, and a numbers needed to treat (NNT) of 4.  This positive NNT suggests that for every 4 
Luongo, Sofosbuvir for Hepatitis C  7 
 
patients treated in the experimental group, one more will achieve SVR24 than compared to the 
control group.  Additionally, the p-value for the study equaled 0.0006 (Table 2). 
 The most common adverse events reported by Lawitz, Lalezari, et al6 were fatigue, 
headache, nausea, and chills.  Using fatigue for comparison, 68% in the experimental group 
(EER) reported the symptom as opposed to 54% in the placebo group (CER).  This resulted in a 
RRR of 26%, an ARR of 14%, and a NNH of 8.  This implies that for every 8 patients treated, 
one more will have fatigue in the experimental group compared to the control group (Table 3). 
In the third study, Lawitz, Mangia et al7 conducted an open-label, active-controlled RCT, 
dubbed the FISSION study, using patients with HCV genotypes 2 and 3.  Of the 499 patients 
who started treatment, 256 underwent treatment in the experimental group with 400mg 
Sofosbuvir plus RBV for 12 weeks.  The other 243 patients, assigned to the control group, 
received PEG and RBV for 24 weeks.  All subjects who received at least one dose of study drug 
were analyzed in the group to which they were randomized.  Both the experimental and control 
groups obtained an equal percentage of patients that acquired sustained virological response at 
12 weeks post-treatment (SVR12).  Since CER and EER were both 67%, statistical analysis 
resulted in a RBI, ABI, and NNT of 0.  A 95% CI (-7.5 to 8.0) and p-value of <0.001 were also 
reported (Table 2). 
Similar to the other two RCTs, the most self-reported adverse events in Lawitz, Mangia 
et al7 were fatigue, headache, nausea, and insomnia.  Using fatigue for calculations, 55.1% of 
patients in the control group (CER) and 35.9% in the experimental group (EER) experienced this 
adverse event.  This resulted in a RRR of -34.8%, an ARR of -19.2%, and a NNH of -6, which 
suggests that for every 6 patients treated, one fewer will experience the adverse event of fatigue 
in the Sofosbuvir group compared to the control group (Table 3).   
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Table 2: Efficacy of Treatment (Experimental vs. Control) 
Study CER (%) 
EER 
(%) 
RBI 
(%) 
ABI 
(%) NNT 95% CI p-value 
Gane, et al5 100 100 0 0 0 69 to 100 ----- 
Lawitz, 
Lalezari, et al6 58 89 53 14 4 11 to 49 0.0006 
Lawitz, 
Mangia, et al7 67 67 0 0 0 -7.5 to 8.0 <0.001 
 
 
Table 3: Adverse Event of Fatigue from Treatment (Experimental vs. Control) 
Study CER (%) EER (%) RRR (%) ARR (%) NNH (%) 
Gane, et al5 45 10 -77.8 -35 -2 
Lawitz, Lalezari, et al6 54 68 26 14 8 
Lawitz, Mangia, et al7 55.1 35.9 -34.8 -19.2 -6 
 
 
DISCUSSION 
 This systematic review compared three RCTs for the safety and efficacy of Sofosbuvir 
and Ribavirin in the treatment of chronic HCV infection using participates who were 18 years of 
ago or older with treatment-naïve chronic HCV genotypes 1, 2, or 3.  In Gane et al5, a 12-week 
regimen of Sofosbuvir plus RBV proved to be safer but just as effective as Sofosbuvir plus PEG 
and RBV for treatment of chronic HCV genotypes 2 and 3.  People with cirrhosis were excluded 
from participating in this study.  Cirrhosis has been associated with a reduced response to 
treatment, thus results may be skewed.  Furthermore, the sample size of both the experimental 
and control groups were both small at 10 and 11 participants, respectively.  Results, then, may be 
insufficient. 
Lawitz, Lalezari and colleagues6 examined the chronic HCV genotype 1 treatment 
regimen of Sofosbuvir 400mg plus PEG and RBV in comparison to placebo, PEG, and RBV for 
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12 weeks.  Results show that Sofosbuvir-PEG-RBV was more effective yet had more adverse 
events than the control group.  It should be noted that most of the adverse events in the 
experimental group, such as that of fatigue, were noticed during treatment with PEG and RBV as 
opposed to Sofosbuvir.  As with Gane et al5, people with cirrhosis were excluded from 
participating in the study which could have altered the results. 
In the 3rd study, Lawitz, Mangia et al7, the 12-week regimen of Sofosbuvir plus RBV 
showed fewer adverse events but equal efficacy to PEG-RBV for treatment of HCV genotypes 2 
and 3.  In this study, 20% and 21% of participants in the experimental and control groups, 
respectively, had cirrhosis, which affected treatment efficacy and incidence of adverse events.  
Furthermore, efficacy was only measured to week 12 post-treatment (SVR12), which, although 
sufficient, could have been measured to week 24 (SVR24) for better results. 
In regards to safety, the author chose to only address one of the most common self-
reported adverse events, making it an outcome that directly affects the patient, or rather, patient-
oriented evidence that matters (POEM).  It is known, however, that treatment with PEG can 
cause hematologic anomalies such as cytopenia.5  It should be noted that this was seen in each of 
the three RCTs when participants were treat with PEG.  Furthermore, in the large cohort 
FISSION study in Lawitz, Mangia et al7 it was discovered that “adverse events associated with 
various organ systems” were consistently higher in the PEG-RBV control group as opposed to 
the experimental group of Sofosbuvir-RBV.7   
Overall, Sofosbuvir, itself, has been well tolerated in all clinical trials, thus far.  Potential 
drug interactions include certain anticonvulsants, antimycobacterials, HIV protease inhibitors, 
and the herbal supplement St. John's wort. 9  Each of these interactions may decrease the level of 
available Sofosbuvir.  It has also been discovered that Sofosbuvir has a high genetic barrier for 
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resistance, meaning that, unless there are many crucial genetic mutations, it should remain an 
effective treatment.  The biggest downside to Sofosbuvir, which was only recently FDA 
approved in December 2013, is that it costs a staggering $1,000 for one 400mg pill, resulting in a 
total cost of $84,000 after completion of a 12-week course.9  Although highly effective, efficient, 
and safe, the elated price may deter insurance companies or individuals from covering the 
treatment.   
 
CONCLUSION 
 
 In conclusion, it can be deduced that Sofosbuvir plus RBV is safer, yet, statistically, 
nearly equal in efficacy to treatment with PEG and RBV.  Given that PEG is a weekly 
subcutaneous injection with many side effects, it would be more beneficial to receive treatment 
with Sofosbuvir. 
While each RCT carried similar results, future large cohort studies should be done with 
standardized parameters such as using one specific genotype or fully excluding or including 
participants with cirrhosis.  Although the RCTs included smaller analyses that addressed these 
variations, the primary end points of safety and efficacy included all patients.  Additionally, to 
further confirm efficacy in each RCT and rule out relapse of HCV, a one-year post-treatment 
SVR measurement should be done.   
Each of these three RCTs examined additional treatment regimens besides the 
experimental and control groups.  Such alterations included a different dose of Sofosbuvir or 
varying amounts of PEG treatments.  For commonality’s sake, the author of this systematic 
review chose the most suitable comparison groups.  With that said, the only RCT that 
specifically contrasted the treatment of Sofosbuvir and RBV with that of PEG and RBV was 
Lawitz, Mangia, et al7.  Although this study had the largest cohort, it compared treatment with 
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the experimental group for 12 weeks versus 24 weeks for the control group.  One might argue 
that given a reduced treatment time of 12 weeks, the results would have pointed in favor of 
Sofosbuvir plus RBV for the best efficacy.  Additionally, the study observed treatment in 
patients with genotypes 2 and 3, rather than the more common genotype 1 HCV infection.  
Therefore, for a more accurate analysis, another RCT could be performed comparing 12 weeks 
of Sofosbuvir and RBV treatment with 12 weeks of PEG and RBV in patients with genotype 1 
HCV infections.
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